Evaluation of dose, volume and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study

Standard

Evaluation of dose, volume and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study. / Peters, S; Merta, J; Schmidt, L; Jazmati, D; Kramer, P H; Blase, C; Tippelt, S; Fleischhack, G; Stock, A; Bison, B; Rutkowski, S; Pietsch, T; Kortmann, R D; Timmermann, B.

in: NEURO-ONCOLOGY, Jahrgang 24, Nr. 7, 01.07.2022, S. 1193-1202.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Peters, S, Merta, J, Schmidt, L, Jazmati, D, Kramer, PH, Blase, C, Tippelt, S, Fleischhack, G, Stock, A, Bison, B, Rutkowski, S, Pietsch, T, Kortmann, RD & Timmermann, B 2022, 'Evaluation of dose, volume and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study', NEURO-ONCOLOGY, Jg. 24, Nr. 7, S. 1193-1202. https://doi.org/10.1093/neuonc/noab301

APA

Peters, S., Merta, J., Schmidt, L., Jazmati, D., Kramer, P. H., Blase, C., Tippelt, S., Fleischhack, G., Stock, A., Bison, B., Rutkowski, S., Pietsch, T., Kortmann, R. D., & Timmermann, B. (2022). Evaluation of dose, volume and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study. NEURO-ONCOLOGY, 24(7), 1193-1202. https://doi.org/10.1093/neuonc/noab301

Vancouver

Bibtex

@article{cba486d3f6554be6ba33b63ba5e52a0f,
title = "Evaluation of dose, volume and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study",
abstract = "BACKGROUND: Radiotherapy (RT) of ependymoma in children is an important part of the interdisciplinary treatment concept. However, feasibility and dose concepts are still under investigation, particularly in very young children. The aim of this study was to evaluate the standard dose and volume of proton therapy (PT) in children with ependymoma.METHODS: In this analysis, 105 patients with localized, intracranial ependymoma under the age of 18 years treated with PT between 2013 and 2018 were included. Patient characteristics, treatment, outcome, and follow-up data were analyzed using descriptive statistics, Kaplan-Meier, and Cox regression analysis.RESULTS: The median age of patients at PT was 2.8 years (0.9-17.0 years). The molecular subgroup analysis was performed in a subset of 50 patients (37 EP-PFA, 2 EP-PFB, 7 EP-RELA, 2 EP-YAP, 2 NEC [not elsewhere classified]). The median total dose was 59.4 Gy (54.0-62.0 Gy). The median follow-up time was 1.9 years. The estimated 3-year overall survival (OS), local control (LC), and progression-free survival (PFS) rates were 93.7%, 74.1%, and 55.6%, respectively. Within univariable analysis, female gender and lower dose had a positive impact on OS, whereas age ≥4 years had a negative impact on OS and PT given after progression had a negative impact on PFS. In the multivariable analysis, multiple tumor surgeries were associated with lower PFS. New ≥3° late toxicities occurred in 11 patients.CONCLUSION: For children with localized ependymoma, PT was effective and well tolerable. Multiple surgeries showed a negative impact on PFS.",
author = "S Peters and J Merta and L Schmidt and D Jazmati and Kramer, {P H} and C Blase and S Tippelt and G Fleischhack and A Stock and B Bison and S Rutkowski and T Pietsch and Kortmann, {R D} and B Timmermann",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.",
year = "2022",
month = jul,
day = "1",
doi = "10.1093/neuonc/noab301",
language = "English",
volume = "24",
pages = "1193--1202",
journal = "NEURO-ONCOLOGY",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - Evaluation of dose, volume and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study

AU - Peters, S

AU - Merta, J

AU - Schmidt, L

AU - Jazmati, D

AU - Kramer, P H

AU - Blase, C

AU - Tippelt, S

AU - Fleischhack, G

AU - Stock, A

AU - Bison, B

AU - Rutkowski, S

AU - Pietsch, T

AU - Kortmann, R D

AU - Timmermann, B

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - BACKGROUND: Radiotherapy (RT) of ependymoma in children is an important part of the interdisciplinary treatment concept. However, feasibility and dose concepts are still under investigation, particularly in very young children. The aim of this study was to evaluate the standard dose and volume of proton therapy (PT) in children with ependymoma.METHODS: In this analysis, 105 patients with localized, intracranial ependymoma under the age of 18 years treated with PT between 2013 and 2018 were included. Patient characteristics, treatment, outcome, and follow-up data were analyzed using descriptive statistics, Kaplan-Meier, and Cox regression analysis.RESULTS: The median age of patients at PT was 2.8 years (0.9-17.0 years). The molecular subgroup analysis was performed in a subset of 50 patients (37 EP-PFA, 2 EP-PFB, 7 EP-RELA, 2 EP-YAP, 2 NEC [not elsewhere classified]). The median total dose was 59.4 Gy (54.0-62.0 Gy). The median follow-up time was 1.9 years. The estimated 3-year overall survival (OS), local control (LC), and progression-free survival (PFS) rates were 93.7%, 74.1%, and 55.6%, respectively. Within univariable analysis, female gender and lower dose had a positive impact on OS, whereas age ≥4 years had a negative impact on OS and PT given after progression had a negative impact on PFS. In the multivariable analysis, multiple tumor surgeries were associated with lower PFS. New ≥3° late toxicities occurred in 11 patients.CONCLUSION: For children with localized ependymoma, PT was effective and well tolerable. Multiple surgeries showed a negative impact on PFS.

AB - BACKGROUND: Radiotherapy (RT) of ependymoma in children is an important part of the interdisciplinary treatment concept. However, feasibility and dose concepts are still under investigation, particularly in very young children. The aim of this study was to evaluate the standard dose and volume of proton therapy (PT) in children with ependymoma.METHODS: In this analysis, 105 patients with localized, intracranial ependymoma under the age of 18 years treated with PT between 2013 and 2018 were included. Patient characteristics, treatment, outcome, and follow-up data were analyzed using descriptive statistics, Kaplan-Meier, and Cox regression analysis.RESULTS: The median age of patients at PT was 2.8 years (0.9-17.0 years). The molecular subgroup analysis was performed in a subset of 50 patients (37 EP-PFA, 2 EP-PFB, 7 EP-RELA, 2 EP-YAP, 2 NEC [not elsewhere classified]). The median total dose was 59.4 Gy (54.0-62.0 Gy). The median follow-up time was 1.9 years. The estimated 3-year overall survival (OS), local control (LC), and progression-free survival (PFS) rates were 93.7%, 74.1%, and 55.6%, respectively. Within univariable analysis, female gender and lower dose had a positive impact on OS, whereas age ≥4 years had a negative impact on OS and PT given after progression had a negative impact on PFS. In the multivariable analysis, multiple tumor surgeries were associated with lower PFS. New ≥3° late toxicities occurred in 11 patients.CONCLUSION: For children with localized ependymoma, PT was effective and well tolerable. Multiple surgeries showed a negative impact on PFS.

U2 - 10.1093/neuonc/noab301

DO - 10.1093/neuonc/noab301

M3 - SCORING: Journal article

C2 - 34964901

VL - 24

SP - 1193

EP - 1202

JO - NEURO-ONCOLOGY

JF - NEURO-ONCOLOGY

SN - 1522-8517

IS - 7

ER -